Cargando…

Antiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions

CONTEXT: Coronary artery disease is highly prevalent among patients with end stage renal disease/hemodialysis (ESRD/HD) and coronary percutaneous interventions (PCI) has been increased by nearly 50% over the past decade. After PCI with stent placement, guidelines recommend dual antiplatelet therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Summaria, Francesco, Giannico, Maria B., Talarico, Giovanni P., Patrizi, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kowsar 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623612/ https://www.ncbi.nlm.nih.gov/pubmed/26528445 http://dx.doi.org/10.5812/numonthly.28099

Ejemplares similares

Oral antiplatelet therapy in the elderly undergoing percutaneous coronary intervention: an umbrella review
por: Biondi-Zoccai, Giuseppe, et al.
Publicado: (2020)

Antiplatelet Therapy and Percutaneous Coronary Interventions
por: Davanzo, Rene Hameau, et al.
Publicado: (2021)

Intensity of antiplatelet therapy and percutaneous coronary intervention
por: Aronow, Wilbert S
Publicado: (2009)

Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention
por: ten Berg, Jurriën M, et al.
Publicado: (2001)

Shortening Dual Antiplatelet Therapy Duration in High-Risk Patients Undergoing Percutaneous Coronary Intervention
por: Greco, Antonio, et al.
Publicado: (2023)

A novel de-escalation antiplatelet therapy for patients with acute coronary syndrome undergoing percutaneous coronary intervention
por: Li, Yachao, et al.
Publicado: (2023)

Meta-analysis of Unguided Deescalation of Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Mohamed, Mohamed M. G., et al.
Publicado: (2022)

Shortened dual antiplatelet therapy in contemporary percutaneous coronary intervention era
por: Han, Jennie, et al.
Publicado: (2021)

Impact of Anemia and Dual Antiplatelet Therapy on Mortality in Patients Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents
por: Wang, Huili, et al.
Publicado: (2015)

Triple versus dual antiplatelet therapy for coronary heart disease patients undergoing percutaneous coronary intervention: A meta-analysis
por: ZHOU, HONG, et al.
Publicado: (2013)

Income and antiplatelet adherence following percutaneous coronary intervention
por: LaRosa, Anna R., et al.
Publicado: (2022)

Transulnar sheathless percutaneous coronary intervention during bivalirudin infusion in high-risk elderly female with non-ST segment elevation myocardial infarction
por: Summaria, Francesco, et al.
Publicado: (2012)

Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands
por: Deiman, B. A. L. M., et al.
Publicado: (2016)

Association of Frailty With Antiplatelet Response Among Elderly Chinese Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
por: Liu, Yang, et al.
Publicado: (2020)

Cost-effectiveness of antiplatelet drugs after percutaneous coronary intervention
por: Wisløff, Torbjørn, et al.
Publicado: (2016)

Resolution of left ventricular postinfarction thrombi in patients undergoing percutaneous coronary intervention using rivaroxaban in addition to dual antiplatelet therapy
por: Makrides, Constantinos Andreas
Publicado: (2016)

Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry
por: Christ, Günter, et al.
Publicado: (2014)

Dual antiplatelet therapy following percutaneous coronary intervention: protocol for a systematic review
por: Elliott, Jesse, et al.
Publicado: (2019)

Dual‐Antiplatelet Therapy After Percutaneous Coronary Intervention: How Short Is Too Short?
por: Mourikis, Philipp, et al.
Publicado: (2023)

Duration of dual antiplatelet therapy following percutaneous coronary intervention on re-hospitalization for acute coronary syndrome
por: Chen, Shih-Chin, et al.
Publicado: (2014)

Duration of dual antiplatelet therapy in patients treated with percutaneous coronary intervention for coronary chronic total occlusion
por: Lee, Seung Hwa, et al.
Publicado: (2017)

Comparison of early clinical outcomes between dual antiplatelet therapy and triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention
por: Park, Jiesuck, et al.
Publicado: (2022)

Reduction or de-escalation of dual antiplatelet therapy intensity or duration in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A mini-review
por: Farag, Mohamed, et al.
Publicado: (2022)

Individualized intensified antiplatelet therapy based on platelet reactivity testing reduces the incidence of cardiovascular events in patients undergoing percutaneous coronary intervention
por: Spartalis, Michael, et al.
Publicado: (2017)

Effectiveness of dual antiplatelet de-escalation therapy on the prognosis of patients with ST segment elevation myocardial infarction undergoing percutaneous coronary intervention
por: Zhao, Zhigang, et al.
Publicado: (2023)

Optimal duration of dual antiplatelet therapy following percutaneous coronary intervention: protocol for an umbrella review
por: Elliott, Jesse, et al.
Publicado: (2017)

The Optimal Strategy of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stent
por: Hu, Mengjin, et al.
Publicado: (2022)

From Coronaries to Cirrhosis: The Role of Percutaneous Coronary Intervention and Dual Antiplatelet Therapy in End-Stage Liver Disease
por: Remillard, Taylor C., et al.
Publicado: (2021)

Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US
por: Wang, Yehua, et al.
Publicado: (2023)

Efficacy and Safety of Prolonged Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients
por: Han, Jialun, et al.
Publicado: (2023)

The Role of Novel Oral Anticoagulants and Antiplatelet Therapy after Percutaneous Coronary Intervention: Individualizing Therapy to Optimize Outcomes
por: Shlofmitz, Evan, et al.
Publicado: (2019)

A Cardiologists’ Survey on the Use of Anticoagulants and Antiplatelets in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Those Undergoing Percutaneous Coronary Intervention in India
por: Kulkarni, Namrata, et al.
Publicado: (2023)

Extended Duration of Dual‐Antiplatelet Therapy After Percutaneous Coronary Intervention: How Long Is Too Long?
por: Howard, Charles E., et al.
Publicado: (2019)

Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI
por: Ki, You-Jeong, et al.
Publicado: (2021)

Percutaneous Coronary Intervention With Dual Antiplatelet Therapy in a Patient With Chronic Subdural Hematoma: Novel Approach
por: Etuk, Aniekeme S, et al.
Publicado: (2022)

Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials
por: Zhou, Yijiang, et al.
Publicado: (2017)

Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention
por: Cavallari, Larisa H., et al.
Publicado: (2018)

CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings
por: Beitelshees, Amber L., et al.
Publicado: (2022)

Short dual antiplatelet therapy and dual antiplatelet therapy de-escalation after primary percutaneous intervention: For whom and how
por: Muthspiel, Marie, et al.
Publicado: (2022)

Hyphema: A Rare Complication of Periprocedural Antiplatelets and Anticoagulants Following Percutaneous Coronary Intervention
por: Gulati, Amit, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o0lqobrei9j6edp1er46f3o39a